Tripp Leavitt
Stanford University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Tripp Leavitt.
Cell Reports | 2013
Ling Liu; Tom H. Cheung; Gregory W. Charville; Bernadette Marie Ceniza Hurgo; Tripp Leavitt; Johnathan Shih; Anne-Christine Brunet; Thomas A. Rando
Summary The ability to maintain quiescence is critical for the long-term maintenance of a functional stem cell pool. To date, the epigenetic and transcriptional characteristics of quiescent stem cells and how they change with age remain largely unknown. In this study, we explore the chromatin features of adult skeletal muscle stem cells, or satellite cells (SCs), which reside predominantly in a quiescent state in fully developed limb muscles of both young and aged mice. Using a ChIP-seq approach to obtain global epigenetic profiles of quiescent SCs (QSCs), we show that QSCs possess a permissive chromatin state in which few genes are epigenetically repressed by Polycomb group (PcG)-mediated histone 3 lysine 27 trimethylation (H3K27me3), and a large number of genes encoding regulators that specify nonmyogenic lineages are demarcated by bivalent domains at their transcription start sites (TSSs). By comparing epigenetic profiles of QSCs from young and old mice, we also provide direct evidence that, with age, epigenetic changes accumulate and may lead to a functional decline in quiescent stem cells. These findings highlight the importance of chromatin mapping in understanding unique features of stem cell identity and stem cell aging.
Plastic Surgery International | 2015
Michael S. Hu; Tripp Leavitt; Samir Malhotra; Dominik Duscher; Michael S. Pollhammer; Graham G. Walmsley; Zeshaan N. Maan; Alexander T. M. Cheung; Manfred Schmidt; Georg M. Huemer; Michael T. Longaker; H. Peter Lorenz
Issues surrounding wound healing have garnered deep scientific interest as well as booming financial markets invested in novel wound therapies. Much progress has been made in the field, but it is unsurprising to find that recent successes reveal new challenges to be addressed. With regard to wound healing, large tissue deficits, recalcitrant wounds, and pathological scar formation remain but a few of our most pressing challenges. Stem cell-based therapies have been heralded as a promising means by which to surpass current limitations in wound management. The wide differentiation potential of stem cells allows for the possibility of restoring lost or damaged tissue, while their ability to immunomodulate the wound bed from afar suggests that their clinical applications need not be restricted to direct tissue formation. The clinical utility of stem cells has been demonstrated across dozens of clinical trials in chronic wound therapy, but there is hope that other aspects of wound care will inherit similar benefit. Scientific inquiry into stem cell-based wound therapy abounds in research labs around the world. While their clinical applications remain in their infancy, the heavy investment in their potential makes it a worthwhile subject to review for plastic surgeons, in terms of both their current and future applications.
Stem Cells International | 2016
Samir Malhotra; Michael S. Hu; Clement D. Marshall; Tripp Leavitt; Alexander T. M. Cheung; Jennifer G. Gonzalez; Harleen Kaur; H. Peter Lorenz; Michael T. Longaker
Chronic wounds are a source of substantial morbidity for patients and are a major financial burden for the healthcare system. There are no current therapies that reliably improve nonhealing wounds or reverse pathological scarring. Mesenchymal stromal cells (MSCs) are a promising source of novel cell-based therapies due to the ease of their harvest and their integral role in the native wound repair process. Recent work has addressed the problems of loss of plasticity and off-target delivery through use of modern bioengineering techniques. Here we describe the applications of MSCs harvested from different sources to the wound healing process and recent advances in delivery of MSCs to targeted sites of injury.
Stem Cell Reviews and Reports | 2016
Graham G. Walmsley; Ryan C. Ransom; Elizabeth R. Zielins; Tripp Leavitt; John Flacco; Michael S. Hu; Andrew S. Lee; Michael T. Longaker; Derrick C. Wan
Bone has the capacity to regenerate and repair itself. However, this capacity may be impaired or lost depending on the size of the defect or the presence of certain disease states. In this review, we discuss the key principles underlying bone healing, efforts to characterize bone stem and progenitor cell populations, and the current status of translational and clinical studies in cell-based bone tissue engineering. Though barriers to clinical implementation still exist, the application of stem and progenitor cell populations to bone engineering strategies has the potential to profoundly impact regenerative medicine.
Organogenesis | 2016
Elizabeth R. Zielins; Ryan C. Ransom; Tripp Leavitt; Michael T. Longaker; Derrick C. Wan
ABSTRACT Limb regeneration is a complex yet fascinating process observed to some extent in many animal species, though seen in its entirety in urodele amphibians. Accomplished by formation of a morphologically uniform intermediate, the blastema, scientists have long attempted to define the cellular constituents that enable regrowth of a functional appendage. Today, we know that the blastema consists of a variety of multipotent progenitor cells originating from a variety of tissues, and which contribute to limb tissue regeneration in a lineage-restricted manner. By continuing to dissect the role of stem cells in limb regeneration, we can hope to one day modulate the human response to limb amputation and facilitate regrowth of a working replacement.
JCI insight | 2017
Michael S. Hu; Graham G. Walmsley; Leandra A. Barnes; Kipp Weiskopf; Robert C. Rennert; Dominik Duscher; Michael Januszyk; Zeshaan N. Maan; Wan Xing Hong; Alexander T. M. Cheung; Tripp Leavitt; Clement D. Marshall; Ryan C. Ransom; Samir Malhotra; Alessandra L. Moore; Jayakumar Rajadas; H. Peter Lorenz; Irving L. Weissman; Geoffrey C. Gurtner; Michael T. Longaker
The monocyte lineage is essential to normal wound healing. Macrophage inhibition or knockout in mice results in impaired wound healing through reduced neovascularization, granulation tissue formation, and reepithelialization. Numerous studies have either depleted macrophages or reduced their activity in the context of wound healing. Here, we demonstrate that by increasing the number of macrophages or monocytes in the wound site above physiologic levels via pullulan-collagen composite dermal hydrogel scaffold delivery, the rate of wound healing can be significantly accelerated in both wild-type and diabetic mice, with no adverse effect on the quality of repair. Macrophages transplanted onto wounds differentiate into M1 and M2 phenotypes of different proportions at various time points, ultimately increasing angiogenesis. Given that monocytes can be readily isolated from peripheral blood without in vitro manipulation, these findings hold promise for translational medicine aimed at accelerating wound healing across a broad spectrum of diseases.
Biochemical and Biophysical Research Communications | 2012
Chin Chen; Tripp Leavitt; Eric Sibley
The homeodomain transcription factor Pdx1 is essential for pancreas formation and functions in pancreatic islets cells to regulate genes involved in maintenance of glucose homeostasis. In order to investigate a role for Pdx1 in intestinal cells, we analyzed the functions and networks associated with genes differentially expressed by Pdx1 overexpression in human Caco-2 cells. In agreement with previous results for intestine isolated from mice with Pdx1 inactivation, functional analysis of genes differentially expressed with Pdx1 overexpression revealed functions significantly associated with nutrient metabolism. Similarly, network analysis examining the interactions among the differentially expressed genes revealed gene networks involved in lipid metabolism. Consistent with defects in maternal nutrient metabolism, mouse pups born to dams with intestine-specific Pdx1 inactivation are underweight and fail to thrive in the neonatal period compared to pups born to control dams. We conclude that Pdx1 mediates lipid metabolism gene networks in intestinal cells and that maternal expression is essential for perinatal growth in mice.
Chronic Wound Care Management and Research | 2016
Tripp Leavitt; Michael S. Hu; Clement D. Marshall; Leandra A. Barnes; Michael T. Longaker; H. Peter Lorenz
Currently available treatments for chronic wounds are inadequate. A clearly effective therapy does not exist, and treatment is often supportive. This is largely because the cellular and molecular processes underlying failure of wound repair are still poorly understood. With an increase in comorbidities, such as diabetes and vascular disease, as well as an aging population, the incidence of these intractable wounds is expected to rise. As such, chronic wounds, which are already costly, are rapidly growing as a tremendous burden to the health-care system. Stem cells have garnered much interest as a therapy for chronic wounds due to their inherent ability to differentiate into multiple lineages and promote regeneration. Herein, we discuss the types of stem cells used for chronic wound therapy, as well as the proposed means by which they do so. In particular, we highlight mesenchymal stem cells (including adipose-derived stem cells), endothelial progenitor cells, and induced pluripotent stem cells. We include the results of recent in vitro and in vivo studies in both animal models and human clinical trials. Finally, we discuss the current studies to improve stem cell therapies and the limitations of stem cell-based thera- peutics. Stem cells promise improved therapies for healing chronic wounds, but further studies
Nature Communications | 2018
Ryan C. Ransom; Deshka S. Foster; Ankit Salhotra; Ruth Ellen Jones; Clement D. Marshall; Tripp Leavitt; Matthew P. Murphy; Alessandra L. Moore; Charles P. Blackshear; Elizabeth A. Brett; Derrick C. Wan; Michael T. Longaker
In the original version of this Article, the authors inadvertently omitted Elizabeth A. Brett, who contributed to the generation of the histology figures, from the author list.This has now been corrected in both the PDF and HTML versions of the Article.
Plastic and reconstructive surgery. Global open | 2017
Ryan C. Ransom; Tripp Leavitt; Leandra A. Barnes; Clement D. Marshall; Derrick C. Wan; Michael T. Longaker
METHODS: Human umbilical cords were harvested following routine delivery and WJ was isolated and purified. In vitro, WJ derived stem cells were placed in osteogenic differentiation medium for 14 days, followed by Alizarin Red S staining to evaluate mineral deposition. In vivo, we used a rat critical-size alveolar bone defect model to investigate the use of Wharton’s Jelly (WJ) in formation of bone. WJ was implanted into a critical size (7 x 4 x 3 mm) alveolar bone defect model representative of cleft palate surgery in 10–11 week old male Sprague-dawley rats. The defects were monitored weekly with CT imaging of living animals to evaluate bone formation in time, followed by histology evaluation at week 24.